Kane Biotech (CVE:KNE) Stock Price Up 8.7% – Should You Buy?

Kane Biotech Inc. (CVE:KNE) was up 8.7% during mid-day trading on Tuesday . The company traded as high as C$0.13 and last traded at C$0.13. Approximately 1,000 shares were traded during trading, a decline of 99% from the average daily volume of 131,581 shares. The stock had previously closed at C$0.12.

Kane Biotech Stock Performance

The company has a market capitalization of C$17.89 million, a PE ratio of -4.33 and a beta of 0.52. The firm has a 50-day moving average of C$0.14 and a two-hundred day moving average of C$0.14. The company has a quick ratio of 0.39, a current ratio of 0.82 and a debt-to-equity ratio of 1,164.24.

Kane Biotech (CVE:KNE) last posted its earnings results on Thursday, August 29th. The company reported C($0.01) earnings per share (EPS) for the quarter. The company had revenue of C$0.62 million for the quarter.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.